🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against superbug strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

The sexually transmitted infection are increasing around the world, with estimates suggesting more than 82 million new cases annually. Particularly high rates are seen in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices at this time.”

Medical experts are increasingly worried about the increase in antibiotic-resistant strains. The World Health Organization has listed it as a "high-priority threat". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Authorization

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in recent days for combating gonorrhoea. This STI can lead to significant complications, including infertility. Scientists believe that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GSK, gained clearance in close succession. This drug, which is employed against urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to develop it.

“This milestone signifies a major breakthrough in the management of superbug gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Research Study Results and Global Access

As per data detailed in a prominent scientific publication, the new drug successfully treated the vast majority of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which involves two antibiotics. The study included hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the rights to register and commercialise the drug in numerous developing nations.

Medical professionals treating patients have voiced positive views. Having a easy-to-administer therapy of this kind is described as a "revolutionary step" for gonorrhoea control. This is considered essential to alleviate the strain of the disease for patients and to halt the transmission of untreatable gonorrhoea worldwide.